2017: A year of innovation and advances
A summary and highlights of new drug therapy approvals and other drug therapy advances in 2017 by FDA's CDER.
In 2017, FDA's Center for Drug Evaluation and Research's (CDER's) new drug therapy approvals helped a wide range of patients suffering from many different medical conditions to gain new hope for improved quality of life and in some cases, improved chances of surviving life-threatening illnesses.
Rare Diseases
Among many other new approvals to help patients with rare diseases, CDER approved the first new treatment for patients with sickle cell disease in almost 20 years and the first non-blood product to treat patients with hemophilia A with inhibitors. For the first time, a treatment is available for adults diagnosed with giant cell arteritis. CDER also approved a new treatment for Batten disease.
Infectious DiseasesCDER approved a new antibiotic to treat certain types of serious skin infections and another to treat complicated urinary tract infections, including kidney infections. They also approved two new treatments for certain patients with chronic hepatitis C; a new drug to help prevent cytomegalovirus infection in patients who have received a bone marrow transplant; and the first therapy in the US to treat Chagas disease.
Neurological DisordersLast year was a particularly productive year for approving new therapies for patients with neurological disorders. CDER approved new therapies to treat patients with tardive dyskinesia, myasthenia gravis, Duchenne muscular dystrophy, certain forms of multiple sclerosis, amyotrophic lateral sclerosis, and for Parkinson's disease.
Cancer Therapies2017 was another strong year for making new cancer therapies available. CDER approved new therapies for certain patients with acute lymphoblastic leukemia; Merkel cell carcinoma; certain forms of relapsed or refractory acute myeloid leukemia; certain forms of lymphoma; recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and specific forms of liver, breast, and colorectal cancer. Furthermore, the first cancer treatment based on a genetic feature of a cancer rather than the location of the body where the tumor originated was also approved.
Other AdvancesCDER approved a new therapy for decreasing heart risk for patients with diabetes; a new drug to treat patients with moderate-to-severe eczema; and three therapies to treat patients with moderate-to-severe plaque psoriasis. CDER also approved the drug in the US with a sensor embedded in the pill that records that the medication was taken. CDER also worked with pharma manufacturers with facilities that were affected by the 2017 Hurricane Season, to address potential drug shortages.
In 2017, CDER approved a wide variety of drug therapies to improve the health of the American public, including the following:
Novel DrugsIn 2017, CDER approved 46 novel drugs either as NMEs, NDAs or BLAs. Of these 46 novel drugs.
In 2017, CDER met its PDUFA goal dates for 100% of the novel drugs approved; it also approved 39 of the 46 novel drugs in the 'first cycle' of review. Thirty six of the 46 novel drugs were approved in the US before receiving approval in any other country.
New Uses and Expanded Uses of Already FDA-Approved DrugsIn 2017, CDER approved five new biosimilars:
Notable approvals in this category include the following:
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance